JP2013517332A - 近視の抑制方法及び近視を抑制する薬物とするアデニル酸シクラーゼ抑制剤の応用 - Google Patents
近視の抑制方法及び近視を抑制する薬物とするアデニル酸シクラーゼ抑制剤の応用 Download PDFInfo
- Publication number
- JP2013517332A JP2013517332A JP2012550317A JP2012550317A JP2013517332A JP 2013517332 A JP2013517332 A JP 2013517332A JP 2012550317 A JP2012550317 A JP 2012550317A JP 2012550317 A JP2012550317 A JP 2012550317A JP 2013517332 A JP2013517332 A JP 2013517332A
- Authority
- JP
- Japan
- Prior art keywords
- myopia
- eye
- adenylate cyclase
- drug
- camp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004379 myopia Effects 0.000 title claims abstract description 23
- 208000001491 myopia Diseases 0.000 title claims abstract description 23
- 229940122658 Adenylate cyclase inhibitor Drugs 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title abstract description 8
- 230000009471 action Effects 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 230000001629 suppression Effects 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 31
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 21
- 230000000877 morphologic effect Effects 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000003786 sclera Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000000835 fiber Substances 0.000 description 5
- 238000001647 drug administration Methods 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001550 time effect Effects 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004423 myopia development Effects 0.000 description 2
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004515 progressive myopia Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000004331 refractive myopia Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
図2は実験眼と対側眼との硝子体眼房の深度の差分図である。
図3は実験眼と対側眼との眼軸の長さの差分図である。
図中、「差分」は実験眼と対側眼とのジオプトリーまたは眼軸のパラメータの差分を指し、溶剤群と投与群との間の比較は一元配置分散分析(ANOVA)が使用され、「*」はP<0.05、「* *」はP<0.01、「* * *」はP<0.001を表す。
Claims (2)
- 近視を抑制する薬物におけるアデニル酸シクラーゼ抑制剤の応用である。
- 前記アデニル酸シクラーゼ抑制剤の型番がSQ22536である、ことを特徴とする請求項1に記載の近視を抑制する薬物におけるアデニル酸シクラーゼ抑制剤の応用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010605133.3 | 2010-12-27 | ||
CN2010106051333A CN102078614B (zh) | 2010-12-27 | 2010-12-27 | 一种抑制近视的方法及腺苷酸环化酶抑制剂作为抑制近视药物的应用 |
PCT/CN2011/084332 WO2012089053A1 (zh) | 2010-12-27 | 2011-12-21 | 腺苷酸环化酶抑制剂作为抑制近视药物的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013517332A true JP2013517332A (ja) | 2013-05-16 |
JP5584316B2 JP5584316B2 (ja) | 2014-09-03 |
Family
ID=44084938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012550317A Expired - Fee Related JP5584316B2 (ja) | 2010-12-27 | 2011-12-21 | 近視の抑制方法及び近視を抑制する薬物とするアデニル酸シクラーゼ抑制剤の応用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9084791B2 (ja) |
EP (1) | EP2589386B8 (ja) |
JP (1) | JP5584316B2 (ja) |
CN (1) | CN102078614B (ja) |
SG (1) | SG181955A1 (ja) |
WO (1) | WO2012089053A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102078614B (zh) * | 2010-12-27 | 2012-07-25 | 温州医学院眼视光研究院 | 一种抑制近视的方法及腺苷酸环化酶抑制剂作为抑制近视药物的应用 |
CN102512677A (zh) * | 2011-12-06 | 2012-06-27 | 温州医学院眼视光研究院 | 鸟苷酸环化酶抑制剂在制备抑制近视药物中的应用 |
CN107898793B (zh) * | 2017-12-01 | 2019-12-24 | 温州医科大学 | 一种抑制近视的方法及制备药物的应用 |
US20210277005A1 (en) * | 2020-03-06 | 2021-09-09 | University Of North Dakota | Proangiogenic compositions and methods of use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09301891A (ja) * | 1996-03-15 | 1997-11-25 | Senju Pharmaceut Co Ltd | 眼軸長制御剤、近視または遠視の予防および治療剤 |
WO2004039965A1 (ja) * | 2002-10-31 | 2004-05-13 | Riken | 多能性幹細胞培養用の組成物とその使用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0834308A1 (en) * | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
CN1179979A (zh) * | 1996-10-03 | 1998-04-29 | 株式会社Lg化学 | 含有多巴胺激动剂和环糊精的用于治疗近视的眼用组合物 |
SE0002211D0 (sv) * | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
AU2003294312A1 (en) * | 2002-11-18 | 2004-07-09 | Celgene Corporation | Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
CN102026642A (zh) * | 2008-05-14 | 2011-04-20 | 财团法人首尔大学校产学协力财团 | 一种含腺苷酸环化酶抑制剂及溶血磷脂酸作为活性成分的调控细胞衰老的组合物 |
WO2010019450A2 (en) * | 2008-08-09 | 2010-02-18 | Nyles Bauer | Synergizing active compounds for treating inflammation and other conditions |
KR101091849B1 (ko) * | 2009-04-28 | 2011-12-12 | 서울대학교산학협력단 | 라이소포스파티드산 및 아데닐일 시클라아제 억제제를 유효성분으로 포함하는 상처 치유 촉진용 약학 조성물 |
CN102078614B (zh) * | 2010-12-27 | 2012-07-25 | 温州医学院眼视光研究院 | 一种抑制近视的方法及腺苷酸环化酶抑制剂作为抑制近视药物的应用 |
-
2010
- 2010-12-27 CN CN2010106051333A patent/CN102078614B/zh active Active
-
2011
- 2011-12-21 EP EP11842457.1A patent/EP2589386B8/en active Active
- 2011-12-21 JP JP2012550317A patent/JP5584316B2/ja not_active Expired - Fee Related
- 2011-12-21 US US13/513,098 patent/US9084791B2/en not_active Expired - Fee Related
- 2011-12-21 SG SG2012047445A patent/SG181955A1/en unknown
- 2011-12-21 WO PCT/CN2011/084332 patent/WO2012089053A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09301891A (ja) * | 1996-03-15 | 1997-11-25 | Senju Pharmaceut Co Ltd | 眼軸長制御剤、近視または遠視の予防および治療剤 |
WO2004039965A1 (ja) * | 2002-10-31 | 2004-05-13 | Riken | 多能性幹細胞培養用の組成物とその使用 |
Non-Patent Citations (2)
Title |
---|
JPN6013047160; The Journal of Biological Chemistry Vol.279, No.18, 2004, p.18121-18126 * |
JPN6013047161; The Journal of Biological Chemistry Vol.284, No.4, 2009, p.2072-2079 * |
Also Published As
Publication number | Publication date |
---|---|
EP2589386A1 (en) | 2013-05-08 |
CN102078614B (zh) | 2012-07-25 |
WO2012089053A1 (zh) | 2012-07-05 |
EP2589386B8 (en) | 2015-08-26 |
US20120270887A1 (en) | 2012-10-25 |
CN102078614A (zh) | 2011-06-01 |
US9084791B2 (en) | 2015-07-21 |
EP2589386B1 (en) | 2015-06-17 |
JP5584316B2 (ja) | 2014-09-03 |
EP2589386A4 (en) | 2013-06-12 |
SG181955A1 (en) | 2012-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Feizi et al. | Therapeutic approaches for corneal neovascularization | |
JP7236753B2 (ja) | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 | |
JP5584316B2 (ja) | 近視の抑制方法及び近視を抑制する薬物とするアデニル酸シクラーゼ抑制剤の応用 | |
Iester | Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension | |
AU2017420911B2 (en) | Method for inhibiting myopia and application in preparing drug | |
CN112057444A (zh) | 巩膜脂代谢通路干预调节剂或脂代谢调节药物作为抑制近视屈光变负和眼轴延长药物的应用 | |
Scelfo et al. | Ocular surface disease in glaucoma patients | |
Guo et al. | Scleral cross-linking in form-deprivation myopic guinea pig eyes leads to glaucomatous changes | |
JP2023099171A (ja) | 緑内障を治療するためのWnt5aの調節 | |
Yamagishi-Kimura et al. | The roles played by FP/EP3 receptors during pressure-lowering in mouse eyes mediated by a dual FP/EP3 receptor agonist | |
Weinreb et al. | Latanoprostene bunod, a dual-acting nitric oxide donating prostaglandin analog for lowering of intraocular pressure | |
JPWO2020009248A1 (ja) | 眼組織の線維化抑制用組成物 | |
Arend et al. | Observational study results in glaucoma patients undergoing a regimen replacement to fixed combination travoprost 0.004%/timolol 0.5% in Germany | |
Ruiz-Lozano et al. | Selective laser trabeculoplasty is safe and effective in patients previously treated with prostaglandin analogs: an evidence-based review | |
Díaz et al. | Experimental model of ocular hypertension in the rat: study of the optic nerve capillaries and action of hypotensive drugs | |
JP4778515B2 (ja) | 角膜疾患治療剤 | |
US20240024348A1 (en) | Methods and compositions for the treatment of glaucoma and related conditions | |
CN107898793A (zh) | 一种抑制近视的方法及制备药物的应用 | |
WO2023029661A1 (zh) | 一种促进miR-21表达的试剂在制备预防和/或治疗糖尿病角膜病变的药物中的应用 | |
Zeng et al. | Protective effect of the natural flavonoid naringenin in mouse models of retinal injury | |
Abu Bakar et al. | Medical Management of Open-Angle Glaucoma: Focus on Mechanisms of Action and Adverse Drug Reactions | |
El-Nimri | Understanding the Link between Myopia and Glaucoma-Clues from Intraocular Pressure and Optic Discs | |
Duan | A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications | |
WO2023048174A1 (ja) | 角膜疾患治療剤 | |
Garg et al. | Hyaluronan and Associated Proteins in the Visual System |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130924 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131224 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140715 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140717 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5584316 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |